Published in final edited form as:

Int Urol Nephrol. 2019 April ; 51(4): 593–599. doi:10.1007/s11255-018-2044-1.

Urine proteomic profiling in patients with nephrolithiasis and cystinuria

Larisa Kovacevic, MD^{1,*}, Joseph A. Caruso, PhD², Hong Lu, PhD¹, Natalija Kovacevic, MD^{1,3}, Yegappan Lakshmanan, MD¹, Nicholas J. Carruthers, PhD², and David S. Goldfarb, MD⁴

⁽¹⁾Department of Pediatric Urology, Children's Hospital of Michigan, Detroit, MI

⁽²⁾Institute of Environmental Health Sciences, Wayne State University, Detroit, MI

⁽³⁾Vattikuti Urology Institute, Henri Ford Hospital, Detroit, MI

⁽⁴⁾Nephrology Division, New York University Langone Medical Center

Keywords

Nephrolithiasis; cystinuria; urine; proteomics

Introduction

Cystinuria is a rare genetic disease that is characterized by impaired transport of cystine and dibasic amino acids in the proximal renal tubule [1]. About half of all cases are transmitted in an autosomal recessive fashion, caused by mutations in the *SLC3A1* gene. This gene encodes rBAT, one of the two protein components of the neutral and basic amino acid transporter [2]. The other half are autosomal dominant with incomplete penetrance, caused by mutations in *SLC7A9* gene, which encodes the light component, the catalytic protein, of the transporter, b^{0,+} AT.

*Corresponding author: Larisa Kovacevic, MD, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, Michigan 48201, lkovacev@dmc.org Phone: +1 313 745 5588.

Conflict of Interest:

Larisa Kovacevic declares that she has no conflict of interest.

Joseph A. Caruso declares that he has no conflict of interest.

Hong Lu declares that she has no conflict of interest.

Natalija Kovacevic declares that she has no conflict of interest.

Yegappan Lakshmanan declares that he has no conflict of interest.

Nicholas J. Carruthers declares that he has no conflict of interest.

David S. Goldfarb declares that he has no conflict of interest.

Ethical approval:

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent:

The urine was obtained for routine urinalysis for clinical care, and would have then been discarded; it was sent to the proteomics laboratory without any personal health identification information. Under these circumstances, analysis of the urine is not considered human subjects research, and therefore informed consent was not required from the participants included in the study.

Patients with cystinuria often present with kidney stones owing to the low solubility of cystine in urine. Their likelihood of forming stones is about 50% [3]. Cystine stones are large and bilateral in the majority of cases. Even though cystine stones represent only 1–2% of all cases with stones, the morbidity is high due to increased recurrence rate, need for multiple surgeries and the risk of developing chronic kidney disease [4]. Renal function in patients with cystine kidney stones is reduced compared to those with non-cystine stones [5], but the cause of this decline is not entirely clear.

The gene mutations identified in cystinuria cannot fully explain kidney stone activity. It has been shown that not all patients with two mutated *SLC3A1* genes will form a stone. Additionally, patients with identical *SLC3A1* or *SLC7A9* genotypes may have onset of stone disease at different ages and with different severity. Therefore, other unidentified factors seem to contribute to kidney stone formation. These factors may include endogenous proteins that could serve as promoters or inhibitors of cystine precipitation, aggregation or epithelial adherence. Proteomics allows simultaneous examination of the patterns of multiple urinary proteins and has become one of the most promising tools in nephrology and urology [6,7]. Using a proteomic approach, we aimed to assess the differences in the concentration and function of urinary proteins between cystinuria and renal stones (CYS) and healthy controls (HC). We postulated that CYS and HC groups would demonstrate different proteomic profiles. We also presumed that CYS patients would have a significant number of proteins involved in abnormal cellular processes including stress, inflammation and immune response, as well as others yet to be identified.

Methods

We compared urinary proteomes of 10 patients with CYS and 10 age- and gender-matched HC, using liquid chromatography-mass spectrometry (LC-MS/MS).

Patient selection

We prospectively enrolled 10 consecutive patients with CYS (35.4±11.2 years, 5 males and 5 females) who presented for routine follow-up visit at New York University Langone Medical Center (nine patients), and at Children's Hospital of Michigan (one patient). All were established patients with cystinuria who had a history of nephrolithiasis. The diagnosis of cystinuria was made when a stone composed of cystine was obtained, and confirmed when urine cystine levels were found to be higher than 75 mg in a 24-hour urine collection analyzed by Litholink Corporation (LabCorp, Chicago, IL)

Random mid-stream fresh urine samples were collected from all participants. At the time of urine collection, patients were asymptomatic (i.e. were not experiencing episodes of urinary tract obstruction and/or urinary tract infections), and were not taking antibiotics. The patients were taking citrate (9/10), tiopronin (5/10) or d-penicillamine (2/10).

HC group consisted of 10 age- and gender-matched volunteer individuals. Random mid-stream fresh urine samples were collected after a detailed history and physical examination was performed. The HC participants denied history of kidney stones, had normal urinalysis by dipstick and were not taking any medications. The urine was obtained for routine

urinalysis for clinical care, and would have then been discarded; it was sent to the proteomics laboratory without any personal health identification information. Under these circumstances, analysis of the urine is not considered human subjects research.

Sample collection and preparation

Random mid-stream fresh urine samples were obtained in sterile cups, prepared within 3 hours of collection (centrifuged at 2500 rpm for 15 minutes) at both institutions and stored as recommended by standardized protocols (developed by the Human Urine and Kidney Proteome Project, HUKPP, and the European Urine and Kidney Proteomics, EuroKUP Initiatives) until use [8]. Following preparation at NYU, de-identified urine specimens and data were sent to our institution. Aliquots were stored at -80°C until all urine specimens were received and processed for proteomic analysis. Each aliquot was used just once. Proteins in each sample were concentrated in a Centricon-type filter. Albumin and IgG were removed by anti-HAS/IgG resin (Sartorius). Protein concentration in each sample was measured by the BCA protein assay (Pierce).

Protein Digestion and Tandem Mass Tag (TMT) Labeling

For HC and CYS groups, 10 μg of depleted urine protein from 10 individual samples were pooled together for 100 μg total, and then dried. Samples were resuspended in 10 μl of 1% SDS, and denatured for 5 min at 95°C . Samples were reduced with 2 mM DTT in 50 mM TEAB for 30 min at 65°C , followed by alkylation with 6 mM iodoacetamide for 30 min at RT. Proteins were digested with 2 μg trypsin overnight at 37°C . Each sample was uniquely labeled using an isobaric TMT tag (Pierce, 1.2 mg) in 50% acetonitrile for 1 h at RT, followed by quenching with 0.5% hydroxylamine. Samples were purified over detergent-removal columns (Pierce) and dried.

2D LC-MS/MS

Peptides were resuspended in 5% acetonitrile/0.1% formic acid/0.005% trifluoroacetic acid and desalted/separated over a 5 μm reverse phase PLRP-S column (Agilent) using mobile phases A (2% acetonitrile) and B (98% acetonitrile), with both buffers adjusted to pH 10.0 using ammonium hydroxide. Thirty first dimension fractions were collected using a TriVersa NanoMate (Advion) system paired to a LTQ-XL mass spectrometer (Thermo). Second dimension peptide separation was performed using reverse phase chromatography (Acclaim PepMap RSLC column, Thermo) under acidic conditions (0.1% formic acid) with an EASY nLC-1000 uHPLC system (Thermo). Peptides were separated over a 90 min gradient and analyzed with an Orbitrap Fusion mass spectrometer (Thermo). MS1 scans were performed in profile mode in the orbitrap at 120,000 resolution. Data-dependent MS2 acquisitions were triggered on the top 10 most abundant ions (charge states 2–7) and fragmented using CID at 35% collision energy in the linear ion trap. Dynamic exclusion was turned on (40 s). TMT tag quantitative was obtained in MS3 using Synchronous Precursor Selection. For this scan, the top 10 fragment ions were fragmented using HCD at 65% collision energy in the orbitrap at a resolution of 60,000 and m/z range of 100–500.

Protein Identification and Quantitation

LC-MS/MS data was analyzed using Proteome Discoverer (Thermo, version 1.4). Peptide identifications were scored using Sequest HT against a reviewed human protein database (Uniprot; downloaded on 2018-04-06; 20,260 entries) and simultaneously against a matched decoy database to determine the false discovery rate (FDR). Searches included up to 2 missed tryptic cleavages and 10 PPM/0.6 Da mass tolerances for parent and fragment ions, respectively. TMT label on peptide N-termini and internal lysine residues, and iodoacetamide derivative of cysteine were specified as fixed modifications. Oxidation of methionine was specified as a variable modification. Peptides were considered a positive identification if they achieved a 0.1 FDR using the Percolator algorithm. Ratios of reporter intensities were calculated as CYS/HC, and *p*-values were calculated using a modified Fisher's exact test. Proteins were considered significant if they displayed a 2-fold increase or decrease in abundance compared with controls, contained at least 2 unique peptide identifications, and had a *p*-value of 0.05.

Pathway analysis

Proteins which met these criteria were analyzed for inclusion into Gene Ontology (GO) classifications. GO is a bioinformatics platform which provides a statistical likelihood that a group of proteins are enriched within a specific biological classification. Protein interaction mapping was used to create a network that indicates the relationship between proteins with increased or decreased abundance using the Reactome FI plugin for Cytoscape (version 3.5).

Results

Patient's characteristics

Serum creatinine values were available in 6 out of the 10 CYS patients, with a mean of 1.09 ± 0.31 mg/dl (range 0.71–1.59 mg/dl). Mean eGFR for these patients was 92 ± 38.1 mL/min/1.73m² (range 46–146 mL/min/1.73m²). The data regarding comorbidities was available only in one patient and included obesity. However, CYS was represented by a relatively young group of people who, besides having cystinuria, are relatively healthy. None of the HC had any comorbidities and their serum creatinine concentrations were not checked.

Proteomic analysis

A total of 2097 proteins were identified by proteomic analysis. Of those, 398 proteins (216 up-regulated and 182 down-regulated) were found to be significantly different between CYS and HC. These significantly and differentially abundant proteins were used to analyze the group differences for biological processes. The top 7 most relevant biological processes over-represented in CYS patients compared to controls by GO analysis are shown in Figure 1. Nearly half of proteins identified in CYS group (191 out of 398) were found to participate in transport processes. The majority of transport proteins were involved in vesicle-mediated transport (150 out of 191) (Figure 2), and 1/3 of them were down regulated (49/150)(Table 1, Supplementary Material). Of those 49, 12 proteins were involved in endosomal transport (Table 1), 9 in transmembrane transport (Table 2), and two were Ras related-proteins, RALA

and Rab 5C. Among endosomal transport-related proteins, there were 6 charged multivesicular body protein (CHMP 1A, 1B, 2A, 2B, 4B and 12 A) and 3 vacuolar sorting-associated proteins (4B, 37D, VTA). Myosin-2 (ratio 12.86) and two actin-related proteins (subunit 2, ratio 7.62 and subunit 1B, ratio 4.9) were highly represented among up-regulated proteins in the vesicle-mediated transport group.

A large number of proteins was found to be involved in inflammation (56 up-regulated and 5 down-regulated proteins) and immune response (98 up-regulated and 41 down-regulated) (Table 2, Supplementary Material), and 52 of those were related to complement activation. We identified 10 complement proteins (C1-C9 and complement factor I). Of those, C1 was the most abundant with all 3 subunits C1Q, R and S being over-represented in CYS group. Protein-protein interaction network modeling of proteins with overall increased and decreased abundance in CYS patients compared to HC is shown in Figure of supplementary material. In this representation, proteins are shown as key nodes or clusters, and known interactions are shown as edges. Consensus GO term for each cluster revealed six biological processes that play a major role in CYS patients: (1) Complement activation, (2) Regulation of complement activation, (3) Endosomal transport, (4) Receptor-mediated endocytosis, (5) Extracellular matrix organization, (6) G-protein coupled receptor signaling. Of those, there were two major down-regulated processes, endosomal transport and G protein coupled receptor signaling pathways. Complement activation and receptor mediated endocytosis were the major up-regulated processes, while extracellular matrix organization included both up and down-regulated proteins.

Discussion

In this study we demonstrate that patients with CYS have a different urine proteomic profile than HC, as hypothesized. Our finding that the transport of proteins is one of the most significant biological processes affected in patients with cystinuria is not surprising, since cystinuria is a disease caused by a defective transport protein. Among various forms of transport, we detected a significant number of urinary proteins involved in vesicle-mediated transport. As part of these transport processes, almost all proteins that participate in endosomal transport were down-regulated. Among those, there were six down-regulated multivesicular bodies proteins (CHMP), and three vacuolar proteins. All these proteins were part of the endosomal transport cluster in the protein mapping, suggesting their interaction. Rab related protein, another protein involved in vesicle-mediated transport [9], was also found to be down-regulated. All these proteins are part of the endocytic pathway and mediate autophagy [9]. CHMP play an essential role in destroying damaged proteins and other particles by incorporating them into intraluminal vesicles and by fusing with lysosomes [9]. CHMP contain endocytic markers such as Rabs, small GTP-binding proteins that participate in the proximal tubule apical endocytic cascade. Additionally, endocytosis is dependent on the integrity of the actin and myosin cytoskeleton, both of which were up-regulated in our study. Myosin and actin play a role in receptor-mediated endocytosis in the proximal renal tubule [10].

The importance of CHMP dysfunction in cystinuric patients is unclear. However, it may indicate an impairment of uptake of cystine crystals into vesicles preventing their

degradation in lysosomes and facilitating their accumulation in the tubular cell with subsequent transfer to the interstitial space where they may initiate plaque formation. Indeed, Randall plaque was initially described in patients with CaOx stones [11] and later also demonstrated in cystinuric stone patients [12]. In a similar fashion, CaOx and CaP crystals have been shown to dissolve within lysosomes following binding and internalization of cultured renal cells [13], but the involvement of CHMP was not described. Indeed, none of the endosomal proteins we found in CYS were part of the urinary proteomes of our patients with nephrolithiasis and hypercalciuria [14], nor were described by others in patients with hyperoxaluria [15], indicating their unique significance in CYS.

Within transmembrane transport processes, we found sodium-amino acid and ammonium transporters to be down regulated, while chloride channels were upregulated. We know that rBAT is a high-affinity protein that, as a component of the transport process at the apical membrane, facilitates sodium-independent uptake of cystine and dibasic amino acids [16]. Our study indicates that other sodium-dependent amino acid transporters may have an important role in cystinuria. The significance of chloride channel up-regulation is unclear but is likely related to defective endocytosis, since the endosomal chloride concentration regulates endocytic efficiency in proximal tubular cells.

We found that a significant number of urinary proteins are involved in inflammatory responses, complement activation and leukocyte mediated immunity in our cystinuric patients. These proteins were part of two clusters on the protein mapping and showed interaction with myosin-2, indicating dysregulation of the cell's cytoskeleton. An increased number of up-regulated inflammatory proteins was also reported in a proteomic analysis of urinary exosomes obtained from 8 cystinuria patients compared to 10 controls [17]. Of those, 18/38 were circulating inflammatory proteins (e.g., complement C3 and C8; fibrinogen alpha, beta, and gamma chain; and serum paraoxonase 1), and 14/38 were derived from neutrophils. Additionally, significant inflammation was found in the urine proteome of patients with nephrolithiasis and hypercalciuria [14], and type 1 primary hyperoxaluria [15]. Altogether, these findings indicate that inflammation plays an important role in the pathogenesis of kidney stone disease irrespective of its metabolic cause.

The major limitation of this study is the small number of samples that were analyzed. This is mainly due to the low incidence of cystinuria in the general population. However, this was intended as a pilot study to generate hypotheses and identify novel biomarkers and intracellular pathways that will require further investigation. Validation using highly specific methods such as ELISA and Western blotting is needed. Another study limitation is the lack of serum creatinine results in about 1/3 of the CYS patients and all HC. However, this should have not affected the results because our study was designed to include pooled urine samples and not individual ones, and to involve healthy individuals as controls. Lastly, most of the CYS patients were on medication that potentially could have affected the urine proteome profile. However, based on their mechanisms of action, it is unlikely that these drugs could change the protein composition of the urine. Thiol drugs bind only to cystine disulfide bridges to form more soluble cysteine-drug complexes without affecting other proteins in the urine. Moreover, there is no reason that citrate, which would change the urine pH in a relatively narrow range, would have affected the proteomic results.

In conclusion, we provide proteomic evidence of impaired endocytosis, dysregulation of actin and myosin cytoskeleton, and inflammation in patients with cystinuria and kidney stone. Endosomal transport proteins were down-regulated mainly through defective CHMP. We can speculate that dysfunction of actin and myosin cytoskeleton facilitates crystal adhesion and engulfment/endocytosis into renal tubular cell, while defective CHMP prevents crystal degradation in lysosomes. It is unclear how the impaired endocytic pathway and CHMP involvement contributes to the development of cystinuria stone disease. Answering these questions may facilitate further understanding of the pathogenesis of the disease which may affect its management.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:

This study was funded by the Rare Kidney Stone Consortium (U54DK083908), a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences' (NCATS). This consortium is funded through a collaboration between NCATS, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The Wayne State University Proteomics Core is supported through the NIH Center Grant P30 ES 020957, the NIH Cancer Center Support Grant P30 CA 022453 and the NIH Shared Instrumentation Grant S10 OD 010700.

We are thankful to Frank Modersitzki for his help with urine specimen collection and processing and with data collection.

Compliance with Ethical Standards:

Funding: This study was funded by the Rare Kidney Stone Consortium (U54DK083908), a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences' (NCATS). This consortium is funded through a collaboration between NCATS, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The Wayne State University Proteomics Core is supported through the NIH Center Grant P30 ES 020957, the NIH Cancer Center Support Grant P30 CA 022453 and the NIH Shared Instrumentation Grant S10 OD 010700.

We are thankful to Frank Modersitzki for his help with urine specimen collection and processing and with data collection.

References

- [1]. Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, Palacín M: Pathophysiology and treatment of cystinuria. *Nat Rev Nephrol* 2010; 6 (7):424–4 [PubMed: 20517292]
- [2]. Pras E, Arber N, Aksentijevich I, Katz G, Schapiro JM, Prosen L, Gruberg L, Harel D, Liberman U, Weissenbach J: Localization of a gene causing cystinuria to chromosome 2p. *Nat Genet* 1994;6(4):415–9 [PubMed: 8054985]
- [3]. Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P: Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. *Pediatr Nephrol* 2005; 20:19–24 [PubMed: 15602663]
- [4]. Dahlberg PJ, Van den Berg CJ, Kurtz SB, Wilson DM, Smith LH: Clinical features and management of cystinuria. *Mayo Clin Proc* 1977;52:533–2 [PubMed: 895195]
- [5]. Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ: The impact of cystinuria on renal function. *J Urol* 2002;168:27–0 [PubMed: 12050485]

- [6]. Thongboonkerd V: Proteomics and kidney stone disease. *Contrib Nephrol* 2008;160:142–8 [PubMed: 18401167]
- [7]. Cadieux PA, Beiko DT, Watterson JD, Burton JP, Howard JC, Knudsen BE, Gan BS, McCormick JK, Chambers AF, Denstedt JD, Reid G: Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. *J Clin Lab Analysis* 2004;18(3):170–5
- [8]. Thongboonkerd V: Practical points in urinary proteomics. *J Proteome Res* 2007;6(10):3881–0 [PubMed: 17824635]
- [9]. Piper RC, Katzmann DJ: Biogenesis and function of multivesicular bodies. *Annu Rev Cell Dev Biol* 2007; 23:519–47 [PubMed: 17506697]
- [10]. Eshbach ML, Weisz OA: Receptor-Mediated Endocytosis in the Proximal Tubule. *Annu Rev Physiol* 2017;79:425–448 [PubMed: 27813828]
- [11]. Bagga HS, Chi T, Miller J, Stoller ML: New insights into the pathogenesis of renal calculi. *Urol Clin North Am* 2013 2;40(1):1–12 [PubMed: 23177630]
- [12]. Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR, Kim SC, Bledsoe SB, Sommer AJ, Grynpas M, Phillips CL, Worcester EM: Renal crystal deposits and histopathology in patients with cystine stones. *Kidney Int* 2006;69(12):2227–35 [PubMed: 16710357]
- [13]. Sabharanjak S, Sharma P, Parton RG: GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42 –regulated, clathrin-independent pinocytic pathway. *Dev Cell* 2002;2:411–23 [PubMed: 11970892]
- [14]. Kovacevic L, Lu H, Caruso JA, Lakshmanan Y: Renal Tubular Dysfunction in Pediatric Urolithiasis: Proteomic Evidence. *Urology* 2016 92:100–5 [PubMed: 26892647]
- [15]. Brooks ER, Hoppe B, Milliner DS, Salido E, Rim J, Krevitt LM, Olson JB, Price HE, Vural G, Langman CB: Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria. *Am J Nephrol* 2016;43(4):293–303 [PubMed: 27161247]
- [16]. Nagamori S, Wiriyaermpul P, Guarch ME, Okuyama H, Nakagomi S, Tadagaki K, Nishinaka Y, Bodoy S, Takafuji K, Okuda S, Kurokawa J, Ohgaki R, Nunes V, Palacín M, Kanai Y: Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. *Proc Natl Acad Sci* 2016; 113(3): 775–780 [PubMed: 26739563]
- [17]. Bourderioux M, Nguyen-Khoa T, Chhuon C, Jeanson L, Tondelier D, Walczak M, Ollero M, Bekri S, Knebelmann B, Escudier E, Escudier B, Edelman A, Guerrero IC: A New Workflow for Proteomic Analysis of Urinary Exosomes and Assessment in Cystinuria Patients. *J Proteome Res* 2014; 14(1):567–777 [PubMed: 25365230]

Figure 1:

Gene ontology (GO) analysis of urinary proteins with relative increased (green) or decreased (red) abundance in adults with cystinuria (Cys) and kidney stones compared to healthy adults. Proteins which had a 2-fold difference in abundance, at least 2 unique spectral identifications and $p < 0.05$ were mapped against GO term lists to determine which biological processes were enriched. *, p -value < 0.05 .

Figure 2:

Gene ontology (GO) analysis of urinary proteins involved in various types of transport with relative increased and decreased abundance in adults with cystinuria (Cys) and kidney stones compared to healthy adults. *, p -value < 0.05 .

Table 1:

Urinary proteins involved in endosomal transport in adult patients with cystinuria and kidney stones with at least 2-fold decreased abundance relative to healthy controls.

Access Number	Protein Name	Cys/Con	P value
VPS37D	Vacuolar protein sorting-associated protein 37D	0.28	<0.001
CHMP1B	Charged multivesicular body protein 1b	0.29	<0.001
TSG101	Tumor susceptibility gene 101 protein	0.30	<0.001
CLN5	Ceroid-lipofuscinosis neuronal protein 5	0.31	<0.001
VPS4B	Vacuolar protein sorting-associated protein 4B	0.34	<0.001
MVB12A	Multivesicular body subunit 12A	0.35	<0.05
CHMP1A	Charged multivesicular body protein 1a	0.37	<0.01
VTA1	Vacuolar protein sorting-associated protein VTA1 homolog	0.37	<0.01
CHMP2A	Charged multivesicular body protein 2a	0.41	<0.001
CHMP2B	Charged multivesicular body protein 2b;CHMP2B;ortholog	0.41	<0.01
RPS27A	Ubiquitin-40S ribosomal protein S27a	0.46	<0.01
CHMP4B	Charged multivesicular body protein 4b	0.49	<0.05

Table 2:

Urinary proteins involved in transmembrane transport in adult patients with cystinuria and kidney stones with at least 2-fold decreased abundance relative to healthy controls.

Access Number	Protein Name	Cys/Con	P value
SLC12A1	Solute carrier family 12 member 1	0.25	<0.001
AQP2	Aquaporin-2	0.32	<0.05
VDAC1	Voltage-dependent anion-selective channel protein 1	0.35	<0.01
RHCG	Ammonium transporter Rh type C	0.38	<0.01
SCN2B	Sodium channel subunit beta-2	0.40	<0.05
SLC38A10	Putative sodium-coupled neutral amino acid transporter 10	0.42	<0.05
ABCB1	Multidrug resistance protein 1	0.43	<0.01
SLC2A5	Solute carrier family 2, facilitated glucose transporter member 5	0.43	<0.01
RPS27A	Ubiquitin-40S ribosomal protein S27a	0.46	<0.01